Study: Immunotherapy helps bladder cancer patients avoid surgery

August 01, 2026 / 11:27 PM

Sharjah 24 – Reuters: Researchers in the United States have shared encouraging findings from a clinical trial evaluating a novel immunotherapy designed to help aggressive bladder cancer patients avoid the need for bladder removal surgery.

Featured in The Lancet Oncology, the study demonstrated that the treatment enabled a portion of patients to stay cancer-free for over two years, while the majority encountered only manageable side effects.

Trial shows reduced need for bladder removal

The clinical trial included 115 high-risk bladder cancer patients who were administered Crytostemogen Grenadineribvic following the failure of standard Bacillus Calmette-Guerin (BCG) therapy.

Results revealed that 81% of the participants successfully avoided radical bladder removal surgery two years post-treatment.

Promising treatment option

Study investigators noted that this immunotherapy offers a viable alternative for high-risk bladder cancer patients, delivering durable clinical responses while minimizing the necessity for major surgical interventions.